Nemolizumab ( DrugBank: Nemolizumab )


1 disease
IDDisease name (Link within this page)Number of trials
51Scleroderma2

51. Scleroderma


Clinical trials : 525 Drugs : 565 - (DrugBank : 148) / Drug target genes : 114 - Drug target pathways : 217
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-jRCT2031210481
20/04/202212/12/2021An Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects with Systemic SclerosisAn Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects with Systemic Sclerosis Systemic SclerosisNemolizumab will be administered subcutaneouslyNishiura TomoyukiNULLRecruiting>= 20age old<= 70age oldBoth8Phase 2Japan
2NCT05214794
(ClinicalTrials.gov)
April 20, 202217/1/2022An Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Systemic SclerosisAn Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Systemic SclerosisSystemic SclerosisDrug: nemolizumabMaruho Co., Ltd.NULLRecruiting20 Years70 YearsAll8Phase 2Japan